Advertisement
CARLSBAD, Calif., Nov. 24, 2018 /PRNewswire-PRWeb/ -- CMR Naviscan Corporation, a company developing technology solutions for high resolution diagnostic imaging, has signed an exclusive licensing agreement with the Mayo Clinic for a group of technologies invented by a team of Mayo physicians and scientists led by Michael O'Connor, Ph.D. The licensed Molecular Breast Imaging (MBI) intellectual property are used in the CMR Molecular Imaging LumaGEM® Molecular Breast Imaging (MBI) System, manufactured and distributed by CMR Naviscan.
The LumaGEM MBI system, with dual-head digital direct conversion gamma imaging, provides high resolution images with less than 2 mm resolution, using a low dose of Tc99 Sestamibi radiotracer. With over 90 percent sensitivity and specificity, LumaGEM MBI® has been shown to significantly improve cancer detection in women with dense breast tissue with fewer false positives relative to anatomical imaging technologies, such as MRI and whole breast ultrasound.
"It has been proven that early cancer detection significantly increases the probability of curing the disease, and Molecular Breast Imaging is an important tool providing highly accurate information that enables early detection. CMR Naviscan is proud to be a partner with Mayo Clinic in making this MBI available through our global distribution channels and for the continued development of the technology," said Tonatiuh Monroy, CMR Naviscan's President.
Researchers have found and published data demonstrating that in women with dense breast tissue, MBI detects an additional 10 cancers per 1000 women screened and provides an incremental cancer detection rate of 250% over mammography (Rhodes et al. Radiology 2011; Rhodes et al. AJR 2016; https://www.mayo.edu/research/faculty/rhodes-deborah-j-m-d/bio-00027482).
"This collaboration is important because it means that MBI technology, pioneered here at Mayo Clinic, will be available to more and more women. We anticipate new improvements in the technology to further reduce radiation dose associated with MBI, while maintaining the high incremental detection rate of MBI over both mammography and tomosynthesis," said Dr. Michael O'Connor, Professor of Radiologic Physics at Mayo.
About CMR Naviscan Corporation: CMR Naviscan is a leader in organ-specific molecular imaging and part of the Compañia Mexicana de Radiologia CGR, S.A. de C.V. (CMR), a global developer and manufacturer of high quality diagnostic imaging equipment and healthcare information systems, including DICOM-compliant imaging software. CMR Naviscan, headquartered in Carlsbad, California, develops and manufactures molecular imaging systems, including the Solo II™ High Resolution Breast PET Imaging (BPI)scanner, which detects breast cancers as small as 1.6 mm, the Stereo Navigator® PET-guided biopsy accessory, and the LumaGEM® Molecular Breast Imaging (MBI) system. CMR Naviscan is US FDA registered and ISO 13485:2012 certified. For more information visit http://www.cmr-naviscan.com/.
Mayo Clinic and Dr. Michael O'Connor have a financial interest in the technology referenced in this news release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.
SOURCE CMR NAVISCAN CORPORATION
Advertisement
The LumaGEM MBI system, with dual-head digital direct conversion gamma imaging, provides high resolution images with less than 2 mm resolution, using a low dose of Tc99 Sestamibi radiotracer. With over 90 percent sensitivity and specificity, LumaGEM MBI® has been shown to significantly improve cancer detection in women with dense breast tissue with fewer false positives relative to anatomical imaging technologies, such as MRI and whole breast ultrasound.
"It has been proven that early cancer detection significantly increases the probability of curing the disease, and Molecular Breast Imaging is an important tool providing highly accurate information that enables early detection. CMR Naviscan is proud to be a partner with Mayo Clinic in making this MBI available through our global distribution channels and for the continued development of the technology," said Tonatiuh Monroy, CMR Naviscan's President.
Researchers have found and published data demonstrating that in women with dense breast tissue, MBI detects an additional 10 cancers per 1000 women screened and provides an incremental cancer detection rate of 250% over mammography (Rhodes et al. Radiology 2011; Rhodes et al. AJR 2016; https://www.mayo.edu/research/faculty/rhodes-deborah-j-m-d/bio-00027482).
"This collaboration is important because it means that MBI technology, pioneered here at Mayo Clinic, will be available to more and more women. We anticipate new improvements in the technology to further reduce radiation dose associated with MBI, while maintaining the high incremental detection rate of MBI over both mammography and tomosynthesis," said Dr. Michael O'Connor, Professor of Radiologic Physics at Mayo.
About CMR Naviscan Corporation: CMR Naviscan is a leader in organ-specific molecular imaging and part of the Compañia Mexicana de Radiologia CGR, S.A. de C.V. (CMR), a global developer and manufacturer of high quality diagnostic imaging equipment and healthcare information systems, including DICOM-compliant imaging software. CMR Naviscan, headquartered in Carlsbad, California, develops and manufactures molecular imaging systems, including the Solo II™ High Resolution Breast PET Imaging (BPI)scanner, which detects breast cancers as small as 1.6 mm, the Stereo Navigator® PET-guided biopsy accessory, and the LumaGEM® Molecular Breast Imaging (MBI) system. CMR Naviscan is US FDA registered and ISO 13485:2012 certified. For more information visit http://www.cmr-naviscan.com/.
Mayo Clinic and Dr. Michael O'Connor have a financial interest in the technology referenced in this news release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.
SOURCE CMR NAVISCAN CORPORATION
